Manifest Mind Conference

Program : October 26, 2019, 9:00 AM - 5:00 PM

Dynamic Psychotherapy in the Era of “Disruptive Psychopharmacology"

Developing Psychotherapy Considerations for Clinical Work with Ketamine and Psychedelic Drugs

This six-hour Saturday conference offers an opportunity to develop training considerations for psychodynamic practitioners with these mind-manifesting substances, and with a particular emphasis on ketamine.

The advent of the office-based psychotherapeutic use of psychedelic (“mind manifesting”) drugs dawned with the FDA approval this year of ketamine for treatment-resistant depression. Active research projects and intense clinical interest suggests that we have entered an era of “Disruptive Psychophamacology[1]” in which MDMA, psilocybin, and possibly others would be next in line for general clinical use in treatment-resisted depression, PTSD, OCD, Substance Use Disorders, Attachment Disorders, and end-of-life care. What special psychotherapy training might be indicated? 

Schedule: 9 am to 5 pm. Reception Follows



To Register go to

You must apply and get pre-approved at the above website. 



Learning Objectives

After attending this conference, participants should be able to:

  1. Identify important factors to consider in the development of ethical standards for ketamine-assisted psychotherapy 
  2. Discuss the indications and contra-indictions for ketamine-assisted psychotherapy 
  3. Describe a psychodynamic framework for psychotherapeutic use of ketamine for treatment-resistant depression 
  4. List the conditions for which research suggests a potential use of psychedelic drugs combined with psychodynamic treatment
  5. Explain the possible psychological risks of having ketamine, MDMA, and the classic psychedelic drugs available for widespread use
  6. List for yourself or your supervisor your own countertransference reactions to dealing with patients who are using psychedelic drugs


Attendees Will Consider the Following Issues

  • Do we need a new model of the mind to be able to sit with and “listen” to patients who are under the influence of these medications
  • What are useful ways of organizing psychotherapy before, during, and following the drug experiences
  • Is the management of expectancy (mental set and physical setting) different with this form of drug-based psychotherapy compared to psychoanalytic psychotherapy
  • Is psychological treatment necessary to the successful clinical use of these drugs, and if so, at what point in the treatment are psychotherapies best employed
  • Is ketamine-assisted psychotherapy relevant to psychoanalytic and psychodynamic training
  • To what extent is a traditional psychodynamic mindset helpful in integrating such experiences into useful insights; to what extent might it interfere
  • Since repeated contemporary studies have demonstrated that “mystical” subjective experiences seem to be significantly correlated with clinical success of these drugs, what is the relation of the dynamic therapist to the exploration of such experiences
  • Is it possible to use these treatments with Attachment Trauma and severely depressed character disordered patients 
  • What are the psychological risks of having ketamine, MDMA, and the classic psychedelic drugs available for wide-spread use
  • What are the appropriate ethical safeguards for this kind of drug-assisted psychodynamic treatment? 



Raymond Bakaitis, Ph.D. - Discussion Leader. Psychologist in Independent Practice; President, Grex, the West Coast Affiliate of the A. K. Rice Institute for the Study of Social Systems; Associate Clinical Professor of Psychology (Retired), U.C.L.A. Department of Psychology; Past-President, Los Angeles County Psychological Association.  

Thomas M Brod MD - Coordinator/Presenter. Dr. Brod is Sr. Faculty at New Center for Psychoanalysis and is in private practice in Los Angeles. He is Associate Clinical Professor, Psychiatry, Geffen UCLA School of Medicine and a Distinguished Life Fellow of the American Psychiatric Association. He has been organizing conferences on Self-Regulation and Intensive Dynamic Psychotherapy since 1982; he also chaired the first modern Symposium on psyilocybin at the American Psychiatric Association annual meeting in 2006.

Lara Edinger, DO MS - Presenter is double-Board Certified as a neurologist and pain managemen t, specializing in the treatment of Complex Regional Pain Syndrome (CRPS). She is a pioneer in the field of ketamine infusion for pain. Dr. Edinger served as chief resident at Drexel University College of Medicine under Dr. Robert Schwartzman, a pioneer in the use of ketamine for the treatment of chronic pain. As a fellow at UVA, she developed new ketamine protocols. She has partnered with psychiatrists for treatment of depression with ketamine. She is the owner and director of Edinger Pain Management . She is Assistant Clinical Professor of Neurology, Geffen UCLA School of Medicine. 

Robin Carhart-Harris, PhD -Video presentation, from BTCI Conference May 16, 2019- Head, Centre for Psychedelic Research Imperial College, London. His PhD is in Psychopharmacology and he has a MA in Psychoanalysis. He has designed and/or carried out human brain imaging studies with a variety of psychedelic compounds, plus a clinical trial of psilocybin for treatment-resistant depression, and a current study comparing psilocybin with escitalopram for major depressive disorder. 

David J Laramie, PhD -Discussion leader- is a health psychologist in private practice in Beverly Hills and at the Akasha Center in Santa Monica. In his work, he is particularly focused on integrative approaches to health and wellness.  

Scott Shannon, MD - Faculty, Featured Speaker. Dr. Shannon founded Wholeness Center, in Fort Collins, in 2010. This innovative clinic provides cross-disciplinary evaluation and care for all mental health concerns. Scott serves as a site Principle Investigator and therapist for the Phase III trial of MDMA assisted psychotherapy for PTSD sponsored by Multidisciplinary Association for Psychedelic Studies (MAPS). He has also published numerous articles about his research on cannabidiol (CBD) in mental health. Currently, Scott works extensively with ketamine-assisted-psychotherapy. He lectures all over the world to professional groups interested in a deeper look at mental health issues, safer tools and a paradigm shifting perspective about transformative care.  

Scott has been a student of consciousness since his honor’s thesis on that topic at the University of Arizona in the 1970s under the tutelage of Andrew Weil. Following medical school, Scott studied Jungian therapy and acupuncture while working as a primary care physician in a rural area for four years. MDMA assisted psychotherapy became a facet of his practice before this medicine was scheduled in 1985. He then completed a Psychiatry residency at Columbia program in New York. Scott studied cross-cultural psychiatry and completed a child/adolescent psychiatry fellowship at the University of New Mexico.  

Scott has published four books on holistic mental health including the first integrative psychiatry textbook for this field in 2001. His pediatric mental health textbook was published in 2014. Scott is a past President of the American Holistic Medical Association and a past President of the American Board of Integrative Holistic Medicine.  


Target Audience:

For Physicians and Licensed Psychotherapists. By application only. To apply, visit 



6.5 CE Credits



$175 standard fee
$150 discounted fee for UCLA and USC psychiatric residents and other licensed trainees. 




IMPORTANT DISCLOSURE INFORMATION FOR ALL LEARNERS: None of the planners and presenters of this CME/CE program have any relevant financial relationships to disclose. 

PHYSICIANS: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Psychoanalytic Association and the New Center for Psychoanalysis. The American Psychoanalytic Association is accredited by the ACCME to provide continuing medical education for physicians. 

The American Psychoanalytic Association designates this Live Activity for the maximum of 5.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  

PSYCHOLOGISTSThe New Center for Psychoanalysis is approved by the American Psychological Association to sponsor continuing education for psychologists. New Center for Psychoanalysis maintains responsibility for this program and its content. Full attendance is required for psychologists to receive credit; partial credit may not be awarded based on APA guidelines. For the psychologists’ records, certificates of attendance are provided at the completion of the course.  

SOCIAL WORKERS, MARRIAGE and FAMILY THERAPISTS (LCSW, LMFT, ASW, IMF, LEP, LPCC, PCCI): The New Center for Psychoanalysis is a continuing education provider that has been approved by the American Psychological Association, a California Board of Behavioral Sciences recognized approval agency. 

REGISTERED NURSES: The New Center for Psychoanalysis is an accredited provider approved by the California Board of Registered Nursing (Provider #CEP1112). Registered Nurses may claim only the actual number of hours spent in the educational activity for credit.